Main menu

Richer insights with adaptive sampling: targeted panels without probes for cancer predisposition, tumor profiling and beyond

Oxford Nanopore's digital panel technology is transforming clinical and translational cancer research, providing probe-free, long-read targeted panels that enable the detection of all variant classes, and methylation in a single, rapid assay.

From inherited cancer risk to tumor profiling and pharmacogenomics, this on-demand webinar presents Oxford Nanopore's off-the-shelf solutions for creating simple, rapid custom panels providing data-rich scalable insights into cancer biology.

In this webinar:

  • Discover how Oxford Nanopore’s hereditary cancer panel uses long-read sequencing to identify all variant classes — SNVs, indels, structural variants, and methylation — in one streamlined workflow, without the need for separate enrichment or bisulfite steps.
  • Learn how digital panels, powered by adaptive sampling, dynamically enriches for regions of interest in real time — offering flexible, probe-free target selection and the ability to customize or update panels instantly as research needs evolve.
  • Explore how Oxford Nanopore’s technology supports a full continuum of cancer research — from hereditary cancer risk assessment to somatic mutation and pharmacogenomic profiling — with rapid, scalable, and data-rich insights for translational and clinical applications.
resources.authors: Claire Attwooll, Senior Director, Clinical Solutions, Oxford Nanopore Technologies

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Modern slavery policy Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag